Algeta and Bayer agree $2.9bn sweetened takeover

Norway's Algeta has accepted a takeover bid from partner Bayer after the German group increased its offer by nearly 8%. The bid, which will see Bayer assume full control of the developer of its prostate cancer radiopharmaceutical Xofigo (radium-223 dichloride), has been upped to $2.9bn from $2.4bn.